Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates.

A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for ...

Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...

Metsera Inc (NASDAQ: MTSR) has been pushing to the upside since its debut on Nasdaq on January 31. But analysts are convinced ...

Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that limitations keep them from expanding their reach. The weekly injections and ...

Jan 31 (Reuters) - Shares of weight-loss drug developer Metsera (MTSR.O), opens new tab surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm ...

Metsera Inc. raised $275 million in its IPO, selling 15.3 million shares for $18 each, according to a statement. It had offered 17.2 million shares for $15 to $17 each. At the IPO price ...

Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug ...